Two drugs in CRC treatment are approved, and they include Bevacizumab, which targets a cancer cell protein called the vascular endothelial growth factor (VEGF), and Cetuximab, which is an epidermal growth factor receptor (EGFR) inhibitor drug used for the treatment of metastatic colorectal cancer [72]. The gene discussed is VEGFA; the disease is colorectal carcinoma.